Societe Generale set a €105.00 ($122.09) price objective on Merck KGaA (FRA:MRK) in a report published on Wednesday, March 27th, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.
A number of other equities analysts have also weighed in on the stock. Kepler Capital Markets set a €108.00 ($125.58) target price on shares of Merck KGaA and gave the stock a buy rating in a research report on Wednesday, December 12th. JPMorgan Chase & Co. set a €100.00 ($116.28) target price on shares of Merck KGaA and gave the company a neutral rating in a research note on Tuesday, January 8th. Sanford C. Bernstein set a €105.00 ($122.09) price target on shares of Merck KGaA and gave the stock a buy rating in a report on Thursday, February 28th. Morgan Stanley set a €88.00 ($102.33) price target on shares of Merck KGaA and gave the stock a neutral rating in a report on Friday, December 14th. Finally, Warburg Research set a €103.00 ($119.77) price target on shares of Merck KGaA and gave the stock a neutral rating in a report on Thursday, March 7th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and five have given a buy rating to the stock. Merck KGaA currently has a consensus rating of Hold and an average price target of €101.15 ($117.62).
Shares of MRK traded down €1.14 ($1.33) during mid-day trading on Wednesday, reaching €93.78 ($109.05). The stock had a trading volume of 684,754 shares. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Story: What is the Rule of 72?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.